Glenmark Pharmaceuticals is currently trading at Rs. 637.75, up by 1.80 points or 0.28% from its previous closing of Rs. 635.95 on the BSE.
The scrip opened at Rs. 636.00 and has touched a high and low of Rs. 638.15 and Rs. 628.75 respectively. So far 11902 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.
Last one week high and low of the scrip stood at Rs. 664.45 and Rs. 628.75 respectively. The current market cap of the company is Rs. 17890.87 crore.
The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.20% and 14.26% respectively.
Glenmark Pharmaceuticals’ Swiss subsidiary -- Glenmark Specialty S.A. has entered into an exclusive licensing agreement with Grandpharma, China (Grandpharma) for commercializing its novel nasal spray Ryaltris in China.
As per the agreement, the company will be responsible to manufacture and supply Ryaltris, while Grandpharma will be responsible for regulatory filing and commercialization of Ryaltris in China. The company will receive an upfront payment, regulatory filing, regulatory approval and commercial milestone payments as well as royalties from Grandpharma for Ryaltris.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
